- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:01 | Why Pfizer Stock Blasted More Than 6% Higher Today | 16 | The Motley Fool | ||
| Mi | Earnings call: Pfizer raises 2024 EPS outlook despite revenue decline | 7 | Investing.com | ||
| Mi | Pfizer plans to be 'very active' in obesity market, but CEO mum on precise R&D plans | 21 | FierceBiotech | ||
| Mi | Dow Jumps 200 Points Following Fed Decision; Pfizer Earnings Top Estimates | 17 | Benzinga.com | ||
| Mi | Pfizer Stock Gets Boost From Better-Than-Expected Earnings | 27 | Investopedia | ||
| Mi | Pfizer Stock Is Near An 11-Year Low - But Is It A Buy On This 'Massive' Upside? | 13 | Investor's Business Daily | ||
| Mi | UPDATE Wall Street: Super Micro -15 Prozent, Nvidia -5 Prozent, Pfizer überrascht | 1.341 | Der Aktionär | Die Anleger am US-Aktienmarkt halten sich am Mittwoch vor der Zinsentscheidung der amerikanischen Notenbank zurück. Der Dow Jones legt um 0,3 Prozent zu, während der S&P 500 mit 0,3 Prozent im Minus... ► Artikel lesen | |
| Mi | Pfizer's strong Vyndaqel sales draw attention to rare disease drug's patent life | 10 | BioPharma Dive | ||
| Mi | Pfizer Reportedly Plans D2C COVID and Migraine Drug Platform | 7 | PYMNTS.com | ||
| Mi | Stocks making the biggest moves midday: Super Micro Computer, Starbucks, Pfizer and more | 15 | CNBC | ||
| Mi | Pfizer sets up DTC marketing platform as Q1 sales beat expectations | 9 | FiercePharma | ||
| Mi | Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised | 34 | Zacks | ||
| Mi | Pfizer Q1 Results: Co lifts profit view on cost cuts, smaller drop in Paxlovid | 13 | Times of India | ||
| Mi | Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With Expectations | 6 | Benzinga.com | ||
| Mi | Pfizer-Aktie: Kurs legt zu (24,9785 €) | 334 | ARIVA.de | Im Plus liegt derzeit die Aktie von Pfizer . Der jüngste Kurs betrug 26,69 US-Dollar. Im US-amerikanischen Wertpapierhandel hat sich heute das Wertpapier von Pfizer zwischenzeitlich um 4,18 Prozent... ► Artikel lesen | |
| Mi | Pfizer Jumps After Raising Its Outlook On The Heels Of A Big Quarterly Beat | 37 | Investor's Business Daily | ||
| Mi | Stocks making the biggest moves premarket: Pfizer, CVS, Amazon, Starbucks and more | 22 | CNBC | ||
| Mi | Pfizer ups full-year earnings outlook | 13 | Sharecast | ||
| Mi | Pfizer 1Q Revenues Down 20% | 16 | Contract Pharma | ||
| Mi | US STOCKS TransMedics, Root, Pfizer | 8 | Reuters |
Seite:
1 2 3 4 5 Weiter >>
1.014 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IM CANNABIS CORP | 1,160 | 0,00 % | Pre-market Movers: IMCC, CVRX, TGTX, ROOT, PLTN. | WOONSOCKET (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 09.00 A.M. ET).In the Green IM Cannabis Corp. (IMCC) is up over 36% at $0.86.
TG... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,365 | 0,00 % | Aquestive stock falls amid Libervant approval, Anaphylm update | ||
| LYRA THERAPEUTICS | 5,270 | +2,13 % | Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | WATERTOWN, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory... ► Artikel lesen | |
| HARROW | 10,410 | 0,00 % | Harrow Health, Inc. Announces Fourth Quarter and Year-End 2023 Financial Results | NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Company also... ► Artikel lesen | |
| OMNIAB | 4,545 | +2,36 % | OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights | EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program... ► Artikel lesen | |
| NEUROGENE | 33,730 | 0,00 % | Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates | NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases... ► Artikel lesen | |
| SUNSHINE BIOPHARMA | 0,860 | 0,00 % | Pre-market Movers: Zhongchao, Redwoods Acquisition Corp., Tritium DCFC, Nexalin Technology, Sunshine Biopharma | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.05 A.M. ET).In the Green Zhongchao Inc. (ZCMD) is up over 96% at $2.83.
Redwoods... ► Artikel lesen | |
| SOLID BIOSCIENCES | 9,540 | 0,00 % | Solid Biosciences Inc.: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases... ► Artikel lesen | |
| ITERUM THERAPEUTICS | 1,590 | +3,25 % | Iterum Therapeutics PLC: Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem | --First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024-- DUBLIN, Ireland and CHICAGO, April 29, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 3,260 | +6,54 % | Reviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia | - FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA)... ► Artikel lesen | |
| PROCESSA PHARMACEUTICALS | 2,220 | 0,00 % | Pre-market Movers: Barfresh Food, Processa Pharmaceuticals, reAlpha Tech, Biophytis, Meta Platforms | ARMONK (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.25 A.M. ET).In the Green Barfresh Food Group, Inc. (BRFH) is up over 96% at... ► Artikel lesen | |
| ELEVAI LABS | 0,678 | 0,00 % | Elevai Labs Inc.: Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments | ||
| INTERCURE | 2,960 | 0,00 % | InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million | NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts... ► Artikel lesen | |
| ALLARITY THERAPEUTICS | 1,370 | 0,00 % | Allarity Therapeutics, Inc.: Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement | Boston (April 29, 2024) - Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,... ► Artikel lesen | |
| BIONANO GENOMICS | 0,970 | +9,83 % | Bionano Genomics: Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing | SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study from Penn State College of Medicine that used optical genome mapping... ► Artikel lesen |
Das Unternehmen PFIZER INC CDR kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 8,050 Euro und damit +0,62 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
